Education
About Us
Working with TipRanks
Follow Us
Ovid Therapeutics Inc (OVID)
NASDAQ:OVID
OVID Stock Chart & Stats
$1.73
-$0.03(-2.93%)
At close: 4:00 PM EST
$1.73
-$0.03(-2.93%)
Day’s Range― - ―
52-Week Range$0.24 - $2.01
Previous CloseN/A
Volume22.63K
Average Volume (3M)1.52M
Market Cap
$126.76M
Enterprise Value$80.61M
Total Cash (Recent Filing)$25.60M
Total Debt (Recent Filing)$13.76M
Price to Earnings (P/E)―
Beta2.38
Next Earnings
Mar 16, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding71,212,360
10 Day Avg. Volume1,191,591
30 Day Avg. Volume1,521,247
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.97
Price to Sales (P/S)116.97
P/FCF Ratio-1.18
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue12.19
Enterprise Value/Gross Profit12.23
Enterprise Value/Ebitda-2.00
Forecast
1Y Price Target
$4.17Price Target Upside141.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DataPositive Phase 1 biomarker and safety data for OV329, including absence of ophthalmic safety signals, support advancement into placebo‑controlled Phase 2 studies by reducing key clinical risk.
Financing And RunwayRecent financing and pro forma cash provide runway to advance OV329 and KCC2 candidates into proof‑of‑concept studies, reducing near‑term funding uncertainty.
Novel Mechanism—KCC2 ProgramFirst‑in‑human KCC2 activator data showed a clean safety profile and EEG changes consistent with target engagement, positioning the KCC2 program as a differentiated approach that could expand treatment options for refractory seizures.
Bears Say
Efficacy RiskInsufficient clinical efficacy for OV329 in controlled trials may limit uptake by key opinion leaders and undermine the commercial case despite favorable early biomarkers.
Execution And Development HistoryA track record of multiple late‑stage program failures underscores execution risk and raises investor concern about translating early signals into successful late‑stage outcomes.
Safety Risk—retinal ToxicityPotential for unexpected safety signals, particularly retinal toxicity concerns with GABA‑AT inhibitors, remains a material risk that could halt development or complicate regulatory review.
Ovid Therapeutics News
OVID FAQ
What was Ovid Therapeutics Inc’s price range in the past 12 months?
Ovid Therapeutics Inc lowest stock price was $0.24 and its highest was $2.01 in the past 12 months.
What is Ovid Therapeutics Inc’s market cap?
Ovid Therapeutics Inc’s market cap is $126.76M.
When is Ovid Therapeutics Inc’s upcoming earnings report date?
Ovid Therapeutics Inc’s upcoming earnings report date is Mar 16, 2026 which is in 65 days.
How were Ovid Therapeutics Inc’s earnings last quarter?
Ovid Therapeutics Inc released its earnings results on Nov 12, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.02.
Is Ovid Therapeutics Inc overvalued?
According to Wall Street analysts Ovid Therapeutics Inc’s price is currently Undervalued.
Does Ovid Therapeutics Inc pay dividends?
Ovid Therapeutics Inc does not currently pay dividends.
What is Ovid Therapeutics Inc’s EPS estimate?
Ovid Therapeutics Inc’s EPS estimate is -0.11.
How many shares outstanding does Ovid Therapeutics Inc have?
Ovid Therapeutics Inc has 71,212,360 shares outstanding.
What happened to Ovid Therapeutics Inc’s price movement after its last earnings report?
Ovid Therapeutics Inc reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went down -2.222%.
Which hedge fund is a major shareholder of Ovid Therapeutics Inc?
Currently, no hedge funds are holding shares in OVID
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ovid Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.17 (141.04% Upside)
$4.17 (141.04% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.6%
Last 30 Days ▲ 17.8%
Last 30 Days ▲ 17.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.07%
12-Months-Change
Fundamentals
Return on Equity
-60.06%
Trailing 12-Months
Asset Growth
-37.80%
Trailing 12-Months
Company Description
Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
OVID Stock 12 Month Forecast
Average Price Target
$4.17
▲(141.04% Upside)
Technical Analysis
Opus Genetics
―
Zentalis Pharmaceuticals
―
Inhibikase Therapeutics
―
Surrozen
―
Biomea Fusion
―
Ownership Overview
17.69% Insiders
4.64% Mutual Funds
25.83% Other Institutional Investors
48.02% Public Companies and Individual Investors